The first patient has been dosed in a Phase 3 clinical trial (NCT03491462) evaluating the effectiveness of Orphazyme’s investigational therapy arimoclomol in the treatment of amyotrophic lateral sclerosis (ALS). One of the disease mechanisms known to be involved in the development of ALS is protein misfolding and aggregation…
Physicians who help amyotrophic lateral sclerosis (ALS) patients die should carefully evaluate their motivations, capacity, and care goals, while also discussing alternatives with their patient, according to researchers. An ALS patient case and commentary, “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” appeared in the…
A new optimized protocol for the use of a noninvasive ventilation technique called bi-level positive airway pressure (Bi-PAP) allows patients with amyotrophic lateral sclerosis (ALS) to live twice as long as they normally would if they received the standard protocol, according to researchers. Their findings were reported in the…
High-tech communication devices, such as eye-tracking computer systems (ETCS), improve quality of life and enable caregiver-independent interaction of severely disabled patients with amyotrophic lateral sclerosis (ALS). However, technical aspects and patients’ cognitive impairment are among the factors still limiting their use. The review study titled “Communication…
Cells that normally help to repair injured muscle tissue — called fibro-adipogenic progenitors — become key players in the muscle wasting and scarring processes in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), a study has found. Conducted by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP), in…
Events leading to the loss of nerve cell fibers called axons appear to take place independent of Sarm1, a molecule known to promote the death of axons in damaged nerve cells, researchers working in mouse model of amyotrophic lateral sclerosis (ALS) report. Rather, the team concluded, other pro-degenerative factors — possibly…
Patients from India with amyotrophic lateral sclerosis (ALS) are younger at disease onset and show longer duration of symptoms compared to patients from western countries, according to researchers. Their study, “The profile of amyotrophic lateral sclerosis in natives of Western Himalayas: Hospital-based cohort study,” appeared…
Gamisoyo-San (GSS), an herbal formula widely used in Asian countries to treat depression, anxiety and other conditions, significantly reduced inflammation and oxidative stress in mice in a study of amyotrophic lateral sclerosis (ALS), suggesting that GSS could be used as an alternative treatment with fewer side effects than conventional…
The accumulation of TDP-43, a widely expressed nuclear protein that binds both DNA and RNA, causes RNA instability in nerve cells derived from patients with amyotrophic lateral sclerosis (ALS). That leads to disruption of energy and protein production, and eventually causes cells’ death. Those findings were described in the…
The active molecule of Petinutin (methsuximide), an anti-epileptic medication, eased motor deficits, extended the lifespan, and showed potent neuroprotective effects in a worm model of amyotrophic lateral sclerosis (ALS), suggesting a potential new treatment strategy for multiple neurodegenerative diseases, a study reports. The study, “α-Methyl-α-phenylsuccinimide ameliorates neurodegeneration…
